Although several other molecular markers, such as FLT3, NPM1, and CEBPA mutations, have been clinically validated and have greatly improved the prognostic classification of AML (3), the patients’ risk cannot be further accurately assessed in NCCN risk stratification subgroups based on current criteria. This evidence concerns the gene FLT3 and acute myeloid leukemia.